NCT05972928

Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients

Effect of Sitagliptin on Clinical, Metabolic and Hormonal Parameters in Polycystic Ovarian Syndrome Patients

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Beni-Suef University · Academic / Other
• Sex: Female
• Age: 20 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The Study aims to determine the proposed positive influence of Sitagliptin in manipulating hormonal , metabolic and inflammatory parameters in the treatment of Polycystic ovary syndrome and subsequent infertility

Detailed description

Study Design : a Prospective Randomized Controlled Trial. A Total of 80 infertile Adult Females aged between 18 and 45 years currently diagnosed with Polycystic ovary syndrome , Meeting the Diagnosis of Rotterdam criteria be diagnosed if any two of the following are present: (1) clinical or biochemical hyperandrogenism, (2) evidence of oligo-anovulation, (3) polycystic appearing-ovarian morphology on ultrasound are to be included in the study. The study will include two groups; each group consists of 40 patients:- Group A : Control Group Group B : Test Group ( will Receive Sitagliptin at a dose of 100 mg every 24 hours

Conditions

• Polycystic Ovary Syndrome

Interventions

Type	Name	Description
DRUG	Sitagliptin 100mg	Sitagliptin at a dose of 100 mg every 24 hours for 3 months

Timeline

• Start date: 2023-07-30
• Primary completion: 2023-10-30
• Completion: 2023-10-30
• First posted: 2023-08-02
• Last updated: 2023-08-02

Locations

1 site across 1 country: Egypt